TEVA Valuation

Teva Pharmaceutical Industries Ltd

Add to Watchlist

Advanced Chart

13.460

+0.640(+4.990%)

Overview
Forecast
Valuation

TEVA Relative Valuation

TEVA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TEVA is overvalued; if below, it's undervalued.

Historical Valuation

Teva Pharmaceutical Industries Ltd (TEVA) is now in the Fair zone, suggesting that its current forward PE ratio of 4.93 is considered Fairly compared with the five-year average of 4.41. The fair price of Teva Pharmaceutical Industries Ltd (TEVA) is between 9.57 to 15.27 according to relative valuation methord.

Relative Value

Fair Zone

9.57-15.27

Current Price：13.14

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.66

P/B

Median3y

1.95

Median5y

1.58

0.00

FCF Yield

Median3y

6.50

Median5y

5.22

Competitors Valuation Multiple

The average P/S ratio for TEVA's competitors is , providing a benchmark for relative valuation. Teva Pharmaceutical Industries Ltd Corp (TEVA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -5.58%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

TEVA.N

Teva Pharmaceutical Industries Ltd